News

Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best medical stocks to buy according to analysts. Bristol-Myers ...
Bristol-Myers Squibb shares snapped six-session losing streak
Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio
Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...
BioPharma Dive4d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Bristol Myers, Bain Capital form new company to develop immunology drugs
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were ...
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...